NFL Biosciences specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents. At the end of 2025, the company has two products in clinical development (NFL-101 and NFL-102) and two products in preclinical development (NFL-201 for the treatment of cannabis addiction and NFL-301 for alcohol addiction).

Employees

Sector

Biotechnology & Medical Research

Calendar

10-22 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change
26-08-28	€0.8320	-2.92%
26-08-27	€0.8570	+4.26%
26-08-26	€0.8220	-0.36%
26-08-25	€0.8250	-6.14%
26-08-24	€0.8790	+9.60%

Delayed Quote Börse Stuttgart

More quotes

Annual profits - Rate of surprise

Company calendar

Market Closed - Börse Stuttgart 15:55:27 2026-08-28 EDT			5-day change	1st Jan Change
0.8320 ^EUR	-2.92%		+0.59%	-19.61%

07-28	NFL Biosciences Submits Application For Authorization Of The Phase 2 Tonic Clinical Trial Evaluating NFL-102 In Smoking Cessation	CI
07-07	Nfl Biosciences Presents Three Scientific Communications on Nfl-101 and Nfl-102 At 2026 Srnt-Europe Conference	CI

Market Cap	11.53M 13.36M 10.81M 9.87M 18.57M 1.27B 18.65M 128M 50.03M 645M 50.15M 49.05M 2.14B	P/E 2024	-9.56x	P/E 2025	-4.62x
Enterprise Value	9.91M 11.48M 9.29M 8.48M 15.96M 1.1B 16.03M 110M 43.01M 554M 43.11M 42.16M 1.84B	EV / Sales 2024	370,592x	EV / Sales 2025	70,790x
Free-Float	85.79%	Yield 2024 *	-	Yield 2025	-

07-28	NFL Biosciences Submits Application For Authorization Of The Phase 2 Tonic Clinical Trial Evaluating NFL-102 In Smoking Cessation	CI
07-07	Nfl Biosciences Presents Three Scientific Communications on Nfl-101 and Nfl-102 At 2026 Srnt-Europe Conference	CI
06-30	NFL Biosciences Successfully Manufactures GMP Clinical Batch Of NFL-102 And Validates Industrial Production Chain	CI
06-30	NFL Biosciences validates industrial-scale production of NFL-102 for smoking cessation
06-01	NFL Biosciences Releases New Results on NFL-101 and Reaffirms Its Personalized Approach to Smoking Cessation	CI
06-01	NFL Biosciences validates breakthrough in personalized medicine
05-26	Glimmers of hope for Middle East peace grow brighter
05-26	NFL Biosciences to File Patent Application for Smoking Cessation Drug-linked Biomarker	MT
05-25	NFL Biosciences files new patent application
05-25	NFL Biosciences Files Patent Application Protecting Predictive Efficacy Biomarker Associated With NFL-101	CI
05-11	NFL Biosciences SA Clarifies Objectives And Evaluation Criteria For Predictive Biomarker Associated With NFL-101	CI
05-04	NFL Biosciences Presents Work On NFL-102 For Smoking Cessation At International Scientific Conferences	CI
04-15	NFL Biosciences SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI

25-10-20	Nfl Biosciences Outlines Its Development Plan for Nfl-101 in Smoking Cessation Following Receipt of Scientific Advice from Several European Agencies and the U.S. Fda	CI
24-10-02	NFL Biosciences: Invest Securities reduces its target
24-07-15	NFL Biosciences: Invest Securities raises its target

NFL Biosciences Stock Börse Stuttgart

Stocks

82F

FR0014003XT0

Biotechnology & Medical Research

Valuation : NFL Biosciences

Chart: NFL Biosciences

Latest news : NFL Biosciences

Analysts' recommendations : NFL Biosciences

Press Releases : NFL Biosciences

News in other languages : NFL Biosciences

Quotes and Performance

Price Extremes

Managers and Directors : NFL Biosciences

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

07-28	NFL Biosciences Submits an Application for Authorization of the Phase 2 TONIC Clinical Trial Evaluating NFL-102 in Smoking Cessation	BU
07-07	International Scientific Recognition for NFL Biosciences: 3 Presentations Selected at the 2026 SRNT-Europe Conference, Including an Oral Presentation on NFL-102	BU
06-30	NFL Biosciences Announces the Successful Manufacturing of a GMP Clinical Batch of NFL-102 and Validates Its Industrial Production Chain	BU
06-01	NFL Biosciences Releases New Results on NFL-101 and Reaffirms Its Personalized Approach to Smoking Cessation	BU
05-25	NFL Biosciences Is Strengthening Its Personalized Medicine Approach to Smoking Cessation With a New Patent Application	BU

07-28	NFL Biosciences dépose la demande d'autorisation de l'étude clinique de phase 2 TONIC évaluant NFL-102 dans le sevrage tabagique
07-07	NFL Biosciences : Bilan semestriel du contrat de liquidité
07-07	Reconnaissance scientifique internationale pour NFL Biosciences : 3 présentations retenues au congrès SRNT-Europe 2026, dont une communication orale sur NFL-102
06-30	NFL Biosciences valide la production industrielle du NFL-102 contre la tabagisme
06-30	NFL Biosciences annonce la fabrication avec succès d’un lot clinique GMP de NFL-102 et valide sa chaîne industrielle de production

1 week	+0.59%
Current month	+9.31%
1 month	+10.44%
3 months	+3.63%
6 months	-24.43%
Current year	-19.61%

Manager	Title	Age	Since
Bruno Lafont CEO	Chief Executive Officer	-	2024-10-16
Guillaume Audema DFI	Director of Finance/CFO	-	-
Violaine Desort Henin CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Ignacio Faus CHM	Chairman	-	2023-02-26
Bruno Lafont CHM	Chairman	-	2024-10-16
Francis Ahner BRD	Director/Board Member	-	2021-05-18

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NFL BIOSCIENCES	-2.92%	+0.59%	-36.04%	-68.84%	13.58M
WUXI APPTEC CO., LTD.	-1.59%	-6.25%	+64.99%	+99.09%	70.64B
ARGENX SE	-1.34%	+1.13%	+47.33%	+90.79%	66.11B
BIONTECH SE	-8.37%	-7.95%	-0.91%	-13.21%	27.98B
INSMED INCORPORATED	-2.35%	-5.23%	-11.89%	+442.77%	26.51B
WUXI BIOLOGICS (CAYMAN) INC.	+0.30%	+2.03%	+59.48%	+14.21%	26.44B
PHARMAESSENTIA CORPORATION	-0.96%	+12.36%	+280.38%	+439.54%	20.4B
GENMAB A/S	-0.51%	+0.70%	+35.85%	-16.21%	20.17B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.91%	-3.47%	+11.03%	+508.52%	15.99B
EXELIXIS, INC.	-1.47%	+1.42%	+41.39%	+147.61%	13.69B
Average	-2.02%	+1.12%	+49.16%	+164.43%	31.99B
Weighted average by Cap.	-1.98%	+1.23%	+56.05%	+151.21%

	2024	2025
Net sales	46 53.28 43.11 39.37 74.08 5.08K 74.38 511.76 199.58 2.57K 200.05 195.66 8.53K	188 217.76 176.19 160.9 302.74 20.77K 304.01 2.09K 815.68 10.51K 817.59 799.64 34.86K
Net income	-2.08M -2.41M -1.95M -1.78M -3.35M -230M -3.36M -23.15M -9.03M -116M -9.05M -8.85M -386M	-3.32M -3.84M -3.11M -2.84M -5.34M -367M -5.37M -36.91M -14.4M -186M -14.43M -14.11M -615M
Net Debt	-2.07M -2.4M -1.94M -1.77M -3.34M -229M -3.35M -23.06M -8.99M -116M -9.01M -8.82M -384M	-1.62M -1.88M -1.52M -1.39M -2.61M -179M -2.62M -18.02M -7.03M -90.55M -7.04M -6.89M -300M

1 week	0.8	0.93
1 month	0.76	0.93
3 years	0.75	3.06
5 years	0.56	4.43